RecruitingPhase 1NCT05752552

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

Sponsor

DeuterOncology

Enrollment

55 participants

Start Date

Dec 20, 2022

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Advanced Solid Tumor Non-small Cell Lung Cancer Non-small Cell Carcinoma Adult Solid Tumor Refractory Tumor Hereditary Renal Papillary Cancer

Summary

This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative. The dose escalation is completed, Part 2 of the study is ongoing.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DO-2 for people with adult solid tumor, advanced solid tumor, and other related conditions. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDO-2

Deuterated MET kinase inhibitor

Locations(13)

Institut Roi Albert II - UC Louvain

Brussels, Belgium

UZA

Edegem, Belgium

Universitair Ziekenhuis Gent

Ghent, Belgium

UZ Leuven

Leuven, Belgium

Institut Bergonie

Bordeaux, France

Institut Cœur Poumon - CHU Lille

Lille, France

Centre Léon Bérard

Lyon, France

Hôpitaux Universitaires de Marseille Timone

Marseille, France

Centre Antoine Lacassagne

Nice, France

Centre Hospitalier Universitaire De Rennes

Rennes, France

Institut Gustave Roussy

Villejuif, France

Radboud UMC

Nijmegen, Netherlands

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Rotterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05752552

Related Trials

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT0718599778 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Collection of Blood From Patients With Cancer

NCT000342161 location

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.

NCT063760971 location

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT0751337646 locations